Toppublicaties

Longcarcinoom

Geselecteerd door: Longcarcinoom
  • juni 2023

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

  • Tsuboi M, Herbst RS, John T, et al.
  • juni 2023

Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer

  • Wakelee H, Liberman M, Kato T, et al.
  • juni 2023

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

  • Paz-Ares L, Champiat S, Lai WV, et al.
  • april 2023

Body composition and lung cancer-associated cachexia in TRACERx

  • Al-Sawaf O, Weiss J, Skrzypski M, et al.
  • april 2023

The evolution of non-small cell lung cancer metastases in TRACERx

  • Al Bakir M, Huebner A, Martínez-Ruiz C, et al.
  • april 2023

Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

  • Karasaki T, Moore DA, Veeriah S, et al.
  • april 2023

Genomic-transcriptomic evolution in lung cancer and metastasis

  • Martínez-Ruiz C, Black JR, Puttick C, et al.
  • april 2023

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

  • Assaf ZJ F, Zou W, Fine AD, et al.
  • april 2023

STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma

  • Hu J, Sánchez-Rivera FJ, Wang Z, et al.
  • maart 2023

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

  • Cascone T, Leung CH, Weissferdt A, et al.
  • oktober 2022

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

  • Jamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
  • oktober 2022

MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer

  • Shunsuke Kitajima, Tetsuo Tani, Benjamin F Springer, et al.
Gedownload van https://medischeoncologie.nl/ op 21-09-2023 om 20:05. Copyright (C) 2023 BPM Medica.

Deel deze pagina